Resource Summary Report

Generated by RRID on Sep 9, 2026

Axl (C89E7) Rabbit mAb

RRID:AB_11217435
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8661, RRID:AB_11217435

Antibody Information

URL: http://antibodyregistry.org/AB_11217435

Proper Citation: Cell Signaling Technology Cat# 8661, RRID:AB_11217435

Target Antigen: Axl

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F

Antibody Name: Axl (C89E7) Rabbit mAb

Description: This recombinant monoclonal targets Axl

Target Organism: mouse, human

Clone ID: C89E7

Antibody ID: AB_11217435

Vendor: Cell Signaling Technology

Catalog Number: 8661

Record Creation Time: 20231110T055729+0000

Record Last Update: 20260829T090433+0000

Ratings and Alerts

No rating or validation information has been found for Axl (C89E7) Rabbit mAb.

No alerts have been found for Axl (C89E7) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Creixell M, et al. (2026) AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer. Cell reports, 45(7), 117717.

Ferrick KR, et al. (2026) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio. Communications biology, 9(1).

Molè MA, et al. (2026) Modeling human embryo implantation in vitro. Cell, 189(1), 87.

Gautier M, et al. (2026) A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity. Cell reports, 45(5), 117351.

Chang CY, et al. (2026) Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats. NPJ Parkinson's disease, 12(1).

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. Cancer research, 85(1), 118.

Baker MJ, et al. (2025) VAV2 Drives EGFR-Mediated Rac1 Responses in Prostate Cancer. Molecular cancer research : MCR, 23(8), 684.

Ge A, et al. (2025) Alexidine is a TAZ-specific small-molecule inhibitor that suppresses breast cancer invasion and metastasis. iScience, 28(12), 114116.

Chocarro-Calvo A, et al. (2025) Fatty acid uptake activates an AXL-CAV1-?-catenin axis to drive melanoma progression. Genes & development, 39(7-8), 463.

Ravichandran KA, et al. (2025) Enhancing Tyro3 signaling ameliorates IL-1? production through STAT1 in Alzheimer's disease models. Journal of leukocyte biology, 117(12).

Caksa S, et al. (2025) Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. Cancer research.

Zhang Y, et al. (2025) A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell reports, 44(12), 116675.

Pirson S, et al. (2025) AXL promotes lymphangiogenesis by amplifying VEGF-C-mediated AKT pathway. Cellular and molecular life sciences : CMLS, 82(1), 95.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Killarney ST, et al. (2025) PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. Cancer discovery, 15(3), 595.

Stewart ML, et al. (2025) CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. Cell reports. Medicine, 102526.

Chocarro-Calvo A, et al. (2024) Phenotype-specific melanoma uptake of fatty acid from human adipocytes activates AXL and CAV1-dependent ?-catenin nuclear accumulation. bioRxiv : the preprint server for biology.

Kulkarni A, et al. (2024) Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription. EMBO reports, 25(9), 3944.

Marquez-Palencia M, et al. (2024) AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer. Cancer research, 84(5), 675.

Yu D, et al. (2024) Feedforward cysteine regulation maintains melanoma differentiation state and limits metastatic spread. Cell reports, 43(7), 114484.